| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8212169 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 21 Pages |
Abstract
The MTD of vorinostat with concurrent SRS was established as 400Â mg. Although no DLTs were observed, 5 patients withdrew before completing the treatment course, a result that emphasizes the need for supportive care during vorinostat administration. There were no local failures. A larger, randomized trial may evaluate both the tolerability and potential local control benefit of vorinostat concurrent with SRS for brain metastases.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Clara Y.H. MD, PhD, Heather A. MD, Joel W. MD, PhD, Mary C. MD, Hsiang-Hsuan Michael MD, Steven D. MD, John R. MD, Leslie A. MD, Griffith R. MD, Scott G. MD,